Page 31 - 《中国药房》2026年7期
P. 31
2025，36（11）：1384-1388. due to valproic acid[J]. Pediatr Int，2016，58（12）：1358-
[14] KATTULA S，BYRNES J R，WOLBERG A S. Fibrinogen 1359.
and fibrin in hemostasis and thrombosis[J]. Arterioscler [23] FRANCHINI M，LIPPI G. Fibrinogen replacement
Thromb Vasc Biol，2017，37（3）：e13-e21. therapy：a critical review of the literature[J]. Blood Trans‐
[15] WOODS A，BRULL D J，HUMPHRIES S E，et al. Gene- fus，2012，10（1）：23-27.
tics of inflammation and risk of coronary artery disease： [24] DANÉS A F，CUENCA L G，BUENO S R，et al. Efficacy
the central role of interleukin-6[J]. Eur Heart J，2000，21 and tolerability of human fibrinogen concentrate admini-
（19）：1574-1583. stration to patients with acquired fibrinogen deficiency
[16] SALVATORE C M，TECHASAENSIRI C，TAGLIABUE and active or in high-risk severe bleeding[J]. Vox Sang，
C，et al. Tigecycline therapy significantly reduces the con‐ 2008，94（3）：221-226.
centrations of inflammatory pulmonary cytokines and che‐ [25] FENGER-ERIKSEN C， LINDBERG-LARSEN M，
mokines in a murine model of Mycoplasma pneumoniae CHRISTENSEN A Q，et al. Fibrinogen concentrate substi‐
pneumonia[J]. Antimicrob Agents Chemother，2009，53 tution therapy in patients with massive haemorrhage and
（4）：1546-1551. low plasma fibrinogen concentrations[J]. Br J Anaesth，
[17] SHI X P，ZUO C C，YU L L，et al. Real-world data of 2008，101（6）：769-773.
tigecycline-associated drug-induced liver injury among [26] LENG B，SHEN C W，GAO T T，et al. Incidence，charac‐
patients in China：a 3-year retrospective study as assessed teristics and risk factors of hypofibrinogenemia associated
by the updated RUCAM[J]. Front Pharmacol，2021，12： with tigecycline：a multicenter retrospective study in China
761167. [J]. Front Pharmacol，2022，13：943674.
[18] JIANG T T，HUANG X H，LIU Q H，et al. Risk factors [27] BUZZATTI E，FORGHIERI F，PATERNO G，et al. In
for tigecycline-associated hepatotoxicity in patients in the BCR-ABL1 positive B-cell acute lymphoblastic leukemia，
intensive care units of 2 tertiary hospitals：a retrospective steroid therapy induces hypofibrinogenemia[J]. J Clin
study[J]. J Clin Pharmacol，2022，62（11）：1426-1434. Med，2022，11（7）：1776.
[19] BRANDTNER A，BACHLER M，FRIES D，et al. Tigecy‐ [28] LEE J K，YOON C S，NA Y O，et al. Risk factors and
cline interferes with fibrinogen polymerization indepen‐ clinical outcomes associated with acquired hypofibrino‐
dent of peripheral interactions with the coagulation system genemia in patients administered hemocoagulase batroxo‐
[J]. Antibiotics，2020，9（2）：84. bin for hemoptysis[J]. J Thorac Dis，2023，15（1）：65-76.
[20] ZHANG Q，ZHOU S M，ZHOU J. Tigecycline treatment [29] LI M X，HE J，DONG G Q，et al. Serum concentration
causes a decrease in fibrinogen levels[J]. Antimicrob threshold and risk factors of tigecycline-induced hypofibri‐
Agents Chemother，2015，59（3）：1650-1655. nogenaemia in critically ill patients[J]. J Antimicrob Che‐
[21] WU X Q，ZHAO P，DONG L，et al. A case report of pa‐ mother，2025，80（1）：200-208.
tient with severe acute cholangitis with tigecycline treat‐ [30] 段蓉，李正翔. 基于德尔菲法和层次分析法构建《药品临
ment causing coagulopathy and hypofibrinogenemia[J]. 床综合评价主题遴选指南》研究问题及主题遴选评估指
Medicine，2017，96（49）：e9124. 标体系[J]. 中国药房，2025，36（7）：789-793.
[22] KARAKAYALı B，ONSAL OZTURK D，YAZAR A S， （收稿日期：2025-11-07 修回日期：2026-03-09）
et al. Hypofibrinogenemia and intra-articular hemorrhage （编辑：林 静）
中国药房 2026年第37卷第7期 China Pharmacy 2026 Vol. 37 No. 7 · 853 ·
